Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Markman

Showing results (31-40 of 545) with videos related to

Pageof 55
Sort By:
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Optimal versus maximally tolerated dose in cancer chemotherapy treatmentM Markman
Seminars in Surgical Oncology|July 1, 1994
Second-line chemotherapy for refractory cancer: intraperitoneal chemotherapyM Markman
Lancet (London, England)|July 3, 1982
Cholecystectomy and carcinoma of the colonM Markman
The New England Journal of Medicine|June 20, 1985
Medical complications of "alternative" cancer therapyM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1997
Thirty-eighth Annual Meeting of the American Society of HematologyM Markman
The Western Journal of Medicine|July 1, 1985
Tuberculous peritonitis developing in a case of documented peritoneal carcinomatosisM Markman
Seminars in Oncology|June 1, 1985
The intracavitary administration of cytarabine to patients with nonhematopoietic malignancies: pharmacologic rationale and results of clinical trialsM Markman
The Western Journal of Medicine|May 1, 1986
Response of paraneoplastic syndromes to antineoplastic therapyM Markman
Obstetrical & Gynecological Survey|September 1, 1987
Intraperitoneal chemotherapy as treatment of ovarian carcinoma: why, how, and when?M Markman
Journal of Cancer Research and Clinical Oncology|March 14, 1998
Paclitaxel as a component of initial chemotherapy of advanced ovarian cancer: is the controversy resolvedM Markman
Pageof 55

Showing results (31-40 of 545) with videos related to

Sort By:
Pageof 55
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Optimal versus maximally tolerated dose in cancer chemotherapy treatmentM Markman
Seminars in Surgical Oncology|July 1, 1994
Second-line chemotherapy for refractory cancer: intraperitoneal chemotherapyM Markman
Lancet (London, England)|July 3, 1982
Cholecystectomy and carcinoma of the colonM Markman
The New England Journal of Medicine|June 20, 1985
Medical complications of "alternative" cancer therapyM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1997
Thirty-eighth Annual Meeting of the American Society of HematologyM Markman
The Western Journal of Medicine|July 1, 1985
Tuberculous peritonitis developing in a case of documented peritoneal carcinomatosisM Markman
Seminars in Oncology|June 1, 1985
The intracavitary administration of cytarabine to patients with nonhematopoietic malignancies: pharmacologic rationale and results of clinical trialsM Markman
The Western Journal of Medicine|May 1, 1986
Response of paraneoplastic syndromes to antineoplastic therapyM Markman
Obstetrical & Gynecological Survey|September 1, 1987
Intraperitoneal chemotherapy as treatment of ovarian carcinoma: why, how, and when?M Markman
Journal of Cancer Research and Clinical Oncology|March 14, 1998
Paclitaxel as a component of initial chemotherapy of advanced ovarian cancer: is the controversy resolvedM Markman
Pageof 55